Express Gene™ Universal Cancer Screening utilizes liquid biopsy technology to provide a comprehensive genetic analysis for the early detection and monitoring of cancer. This non-invasive test analyzes circulating tumor DNA (ctDNA) in your blood, allowing for the identification of genetic mutations associated with various types of cancer. By detecting cancer at its earliest stages, this test empowers you with critical information to take proactive steps in managing your health and treatment.
Identify cancer at its earliest and most treatable stages, significantly improving the chances of successful treatment.
Screen for multiple types of cancer simultaneously, offering a broad assessment of your cancer risk.
Gain insights into specific genetic mutations, allowing for tailored treatment plans that target the unique characteristics of your cancer.
Explore the Genetic Markers Included in Our Cancer Genetic Testing Panel
ACP5, ADA2, ADAM17, ADAR, AP1S3, ASAH1, CARD14, COPA, DDX58, ELANE, HAX1, HTR1A, IFIH1, IL10RA, IL10RB, IL1RN, IL36RN, ISG15, LPIN2, MEFV, MVK, NLRC4, NLRP1, NLRP12, NLRP3, NOD2, OTULIN, PIK3CD, PIK3R1, PLCG2, POLA1, POMP, PRG4, PRKCD, PSENEN, PSMA3, PSMB4, PSMB8, PSMG2, PSTPIP1, RBCK1, RIPK1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, SH3BP2, SLC29A3, TMEM173, TNFAIP3, TNFRSF11A, TNFRSF1A, TREX1, TRNT1, USP18, WDR1
© 2024 ExpressGene. All rights reserved. Unless otherwise indicated, all product names, service names, and logos featured on this website are trademarks owned by ExpressGene, its subsidiaries, or its affiliates. Any use of ExpressGene trademarks, trade names, or trade dress on this website must be authorized in writing by ExpressGene, except for the purpose of identifying ExpressGene’s products or services.